Other equities analysts also recently issued reports about the stock. Piper Jaffray Companies set a $48.00 price objective on shares of Biohaven Pharmaceutical and gave the stock a buy rating in a research note on Thursday, August 16th. Canaccord Genuity set a $40.00 target price on shares of Biohaven Pharmaceutical and gave the company a buy rating in a report on Sunday, July 1st. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a hold rating to a strong sell rating in a report on Tuesday, July 17th. Needham & Company LLC reaffirmed a buy rating and issued a $48.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th. Finally, Morgan Stanley upped their target price on shares of Biohaven Pharmaceutical from $44.00 to $45.00 and gave the company an overweight rating in a report on Tuesday, September 11th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Biohaven Pharmaceutical has a consensus rating of Hold and an average price target of $47.57.
Shares of Biohaven Pharmaceutical stock traded down $0.53 during trading hours on Thursday, reaching $35.21. 6,868 shares of the company’s stock were exchanged, compared to its average volume of 306,280. Biohaven Pharmaceutical has a fifty-two week low of $16.50 and a fifty-two week high of $44.28. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -7.09 and a beta of 1.46.
Several hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $191,000. Quantitative Systematic Strategies LLC bought a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $205,000. Legal & General Group Plc raised its holdings in Biohaven Pharmaceutical by 111.3% in the 1st quarter. Legal & General Group Plc now owns 5,626 shares of the company’s stock valued at $145,000 after acquiring an additional 2,963 shares during the period. BNP Paribas Arbitrage SA raised its holdings in Biohaven Pharmaceutical by 189.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,299 shares of the company’s stock valued at $162,000 after acquiring an additional 4,121 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $291,000. 80.81% of the stock is currently owned by institutional investors.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Recommended Story: How to Invest in an Index Fund
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.